Skip to main content
Erschienen in: Head and Neck Pathology 2/2023

08.12.2022 | Original Paper

A Subset of Salivary Intercalated Duct Lesions Harbors Recurrent CTNNB1 and HRAS Mutations: A Molecular Link to Basal Cell Adenoma and Epithelial-Myoepithelial Carcinoma?

verfasst von: Anne C. McLean, Lisa M. Rooper, Jeffrey Gagan, Lester D. R. Thompson, Justin A. Bishop

Erschienen in: Head and Neck Pathology | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

Intercalated duct lesions (IDLs) are benign salivary gland proliferations that resemble normal intercalated ducts and are subdivided into hyperplastic, adenoma or hybrid types depending on circumscription. While IDLs were historically regarded as non-neoplastic, frequent association with basal cell adenoma (BCA) and epithelial-myoepithelial carcinoma (EMC) has raised the possibility that they are neoplastic precursors.

Methods

In this study, we performed β-catenin immunohistochemistry and targeted molecular analysis on IDLs to clarify their pathogenesis.

Results

We identified 15 IDLs from the parotid glands of eight men and six women with a median age of 65 years (range 42–85 years). These lesions included nine hyperplastic, three adenoma, and three hybrid types. Nuclear β-catenin localization was present in 7 of 13 lesions tested (54%). Next generation sequencing was successfully completed in 12 IDLs, of which seven (58%) had likely oncogenic mutations. These included three recurrent CTNNB1 mutations in hyperplastic (n = 2) and hybrid (n = 1) lesions and two recurrent HRAS hotspot mutations in adenomas.

Conclusion

Despite substantial heterogeneity, these findings confirm that a majority of IDLs are genuinely neoplastic, and some demonstrate molecular overlap with both BCA and EMC, supporting their theorized role as precursors to these tumors. Nevertheless, no oncogenic drivers were present in a significant subset of cases, suggesting that some IDLs may be truly reactive and hyperplastic. As such, IDL appear to represent a diverse morphologic and molecular spectrum that include both neoplastic and hyperplastic lesions. Reconsideration of the boundary between IDL and BCA in the future may be necessary to simplify classification.
Literatur
1.
Zurück zum Zitat Tandler B, Nagato T, Toyoshima K, Phillips CJ. Comparative ultrastructure of intercalated ducts in major salivary glands: a review. Anat Rec. 1998;252(1):64–91.CrossRefPubMed Tandler B, Nagato T, Toyoshima K, Phillips CJ. Comparative ultrastructure of intercalated ducts in major salivary glands: a review. Anat Rec. 1998;252(1):64–91.CrossRefPubMed
2.
Zurück zum Zitat Di Palma S. Epithelial-myoepithelial carcinoma with co-existing multifocal intercalated duct hyperplasia of the parotid gland. Histopathology. 1994;25(5):494–6.CrossRefPubMed Di Palma S. Epithelial-myoepithelial carcinoma with co-existing multifocal intercalated duct hyperplasia of the parotid gland. Histopathology. 1994;25(5):494–6.CrossRefPubMed
3.
Zurück zum Zitat Weinreb I, Seethala RR, Hunt JL, Chetty R, Dardick I, Perez-Ordonez B. Intercalated duct lesions of salivary gland: a morphologic spectrum from hyperplasia to adenoma. Am J Surg Pathol. 2009;33(9):1322–9.CrossRefPubMed Weinreb I, Seethala RR, Hunt JL, Chetty R, Dardick I, Perez-Ordonez B. Intercalated duct lesions of salivary gland: a morphologic spectrum from hyperplasia to adenoma. Am J Surg Pathol. 2009;33(9):1322–9.CrossRefPubMed
4.
Zurück zum Zitat Yu GY, Donath K. Adenomatous ductal proliferation of the salivary gland. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001;91(2):215–21.CrossRefPubMed Yu GY, Donath K. Adenomatous ductal proliferation of the salivary gland. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001;91(2):215–21.CrossRefPubMed
5.
Zurück zum Zitat Mok Y, Pang YH, Teh M, Petersson F. Hybrid intercalated duct lesion of the parotid: diagnostic challenges of a recently described entity with fine needle aspiration findings. Head Neck Pathol. 2016;10(2):269–74.CrossRefPubMed Mok Y, Pang YH, Teh M, Petersson F. Hybrid intercalated duct lesion of the parotid: diagnostic challenges of a recently described entity with fine needle aspiration findings. Head Neck Pathol. 2016;10(2):269–74.CrossRefPubMed
6.
Zurück zum Zitat Berdugo J, Chiosea S, Peel R, Berg A, Seethala RR. Salivary intercalated duct lesions: a single institution prospective study of 230 totally submitted superficial parotid glands. Mod Pathol. 2018;31. Berdugo J, Chiosea S, Peel R, Berg A, Seethala RR. Salivary intercalated duct lesions: a single institution prospective study of 230 totally submitted superficial parotid glands. Mod Pathol. 2018;31.
7.
Zurück zum Zitat Weinreb I, Zhang L, Tirunagari LM, Sung YS, Chen CL, Perez-Ordonez B, et al. Novel PRKD gene rearrangements and variant fusions in cribriform adenocarcinoma of salivary gland origin. Genes Chromosomes Cancer. 2014;53(10):845–56.CrossRefPubMed Weinreb I, Zhang L, Tirunagari LM, Sung YS, Chen CL, Perez-Ordonez B, et al. Novel PRKD gene rearrangements and variant fusions in cribriform adenocarcinoma of salivary gland origin. Genes Chromosomes Cancer. 2014;53(10):845–56.CrossRefPubMed
8.
Zurück zum Zitat Chiosea S, Seethala R, Williams MD. Intercalated duct hyperplasia. In: El-Naggar A, Chan JK, Grandis JR, Takata T, Slootweg PJ, editors. WHO classification of head and neck tumours. Lyon, France: International Agency for Research on Cancer; 2017. p. 197. Chiosea S, Seethala R, Williams MD. Intercalated duct hyperplasia. In: El-Naggar A, Chan JK, Grandis JR, Takata T, Slootweg PJ, editors. WHO classification of head and neck tumours. Lyon, France: International Agency for Research on Cancer; 2017. p. 197.
9.
Zurück zum Zitat Seethala RR, Stenman G. Update from the 4th edition of the World Health Organization classification of head and neck tumours: tumors of the salivary gland. Head Neck Pathol. 2017;11(1):55–67.CrossRefPubMedPubMedCentral Seethala RR, Stenman G. Update from the 4th edition of the World Health Organization classification of head and neck tumours: tumors of the salivary gland. Head Neck Pathol. 2017;11(1):55–67.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Adhikari BR, Nishimura M, Takimoto K, Harada F, Onishi A, Hiraki D, et al. Adenomatous ductal proliferation/hyperplasia in the parotid gland associated without any other pathological lesions; a report and survey of the literatures. Med Mol Morphol. 2018;51(4):244–8.CrossRefPubMed Adhikari BR, Nishimura M, Takimoto K, Harada F, Onishi A, Hiraki D, et al. Adenomatous ductal proliferation/hyperplasia in the parotid gland associated without any other pathological lesions; a report and survey of the literatures. Med Mol Morphol. 2018;51(4):244–8.CrossRefPubMed
11.
Zurück zum Zitat Bilodeau EA, Acquafondata M, Barnes EL, Seethala RR. A comparative analysis of LEF-1 in odontogenic and salivary tumors. Hum Pathol. 2015;46(2):255–9.CrossRefPubMed Bilodeau EA, Acquafondata M, Barnes EL, Seethala RR. A comparative analysis of LEF-1 in odontogenic and salivary tumors. Hum Pathol. 2015;46(2):255–9.CrossRefPubMed
12.
Zurück zum Zitat Chetty R. Intercalated duct hyperplasia: possible relationship to epithelial-myoepithelial carcinoma and hybrid tumours of salivary gland. Histopathology. 2000;37(3):260–3.CrossRefPubMed Chetty R. Intercalated duct hyperplasia: possible relationship to epithelial-myoepithelial carcinoma and hybrid tumours of salivary gland. Histopathology. 2000;37(3):260–3.CrossRefPubMed
14.
Zurück zum Zitat Magliocca KR, Seethala RR. Salivary intercalated duct lesions in transition. Histopathology. 2016;69(4):710–1.CrossRefPubMed Magliocca KR, Seethala RR. Salivary intercalated duct lesions in transition. Histopathology. 2016;69(4):710–1.CrossRefPubMed
15.
Zurück zum Zitat Montalli VA, Martinez E, Tincani A, Martins A, Abreu Mdo C, Neves C, et al. Tubular variant of basal cell adenoma shares immunophenotypical features with normal intercalated ducts and is closely related to intercalated duct lesions of salivary gland. Histopathology. 2014;64(6):880–9.CrossRefPubMed Montalli VA, Martinez E, Tincani A, Martins A, Abreu Mdo C, Neves C, et al. Tubular variant of basal cell adenoma shares immunophenotypical features with normal intercalated ducts and is closely related to intercalated duct lesions of salivary gland. Histopathology. 2014;64(6):880–9.CrossRefPubMed
16.
Zurück zum Zitat Seki N, Yamazaki N, Ikeda T, Hadara H, Himi T. A symptomatic case of adenomatous ductal proliferation/hyperplasia with a large cystic lesion. Case Rep Oncol. 2017;10(2):676–82.CrossRefPubMedPubMedCentral Seki N, Yamazaki N, Ikeda T, Hadara H, Himi T. A symptomatic case of adenomatous ductal proliferation/hyperplasia with a large cystic lesion. Case Rep Oncol. 2017;10(2):676–82.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Ohtomo R, Mori T, Shibata S, Tsuta K, Maeshima AM, Akazawa C, et al. SOX10 is a novel marker of acinus and intercalated duct differentiation in salivary gland tumors: a clue to the histogenesis for tumor diagnosis. Mod Pathol. 2013;26(8):1041–50.CrossRefPubMed Ohtomo R, Mori T, Shibata S, Tsuta K, Maeshima AM, Akazawa C, et al. SOX10 is a novel marker of acinus and intercalated duct differentiation in salivary gland tumors: a clue to the histogenesis for tumor diagnosis. Mod Pathol. 2013;26(8):1041–50.CrossRefPubMed
19.
Zurück zum Zitat Li B, Jie W, He H. Myb immunohistochemical staining and fluorescence in situ hybridization in salivary rare basaloid lesions. Front Oncol. 2020;10:870.CrossRefPubMedPubMedCentral Li B, Jie W, He H. Myb immunohistochemical staining and fluorescence in situ hybridization in salivary rare basaloid lesions. Front Oncol. 2020;10:870.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Chenevert J, Duvvuri U, Chiosea S, Dacic S, Cieply K, Kim J, et al. DOG1: a novel marker of salivary acinar and intercalated duct differentiation. Mod Pathol. 2012;25(7):919–29.CrossRefPubMed Chenevert J, Duvvuri U, Chiosea S, Dacic S, Cieply K, Kim J, et al. DOG1: a novel marker of salivary acinar and intercalated duct differentiation. Mod Pathol. 2012;25(7):919–29.CrossRefPubMed
21.
Zurück zum Zitat Chiosea S, Di Palma S, Thompson LDR, Weinreb I, Williams MD. Intercalated duct adenoma and hyperplasia. In WHO classification of head and neck tumours, WHO Classification of Tumours Editorial Board (ed.). Lyon, France: International Agency for Research on Cancer, 2022. Chiosea S, Di Palma S, Thompson LDR, Weinreb I, Williams MD. Intercalated duct adenoma and hyperplasia. In WHO classification of head and neck tumours, WHO Classification of Tumours Editorial Board (ed.). Lyon, France: International Agency for Research on Cancer, 2022.
22.
Zurück zum Zitat Agaimy A, Ihrler S, Baneckova M, Costes Martineau V, Mantsopoulos K, Hartmann A, et al. HMGA2-WIF1 rearrangements characterize a distinctive subset of salivary pleomorphic adenomas with prominent trabecular (canalicular adenoma-like) morphology. Am J Surg Pathol. 2022;46(2):190–9.CrossRefPubMed Agaimy A, Ihrler S, Baneckova M, Costes Martineau V, Mantsopoulos K, Hartmann A, et al. HMGA2-WIF1 rearrangements characterize a distinctive subset of salivary pleomorphic adenomas with prominent trabecular (canalicular adenoma-like) morphology. Am J Surg Pathol. 2022;46(2):190–9.CrossRefPubMed
23.
Zurück zum Zitat Bishop JA, Weinreb I, Swanson D, Westra WH, Qureshi HS, Sciubba J, et al. Microsecretory adenocarcinoma: a novel salivary gland tumor characterized by a recurrent MEF2C-SS18 Fusion. Am J Surg Pathol. 2019;43(8):1023–32.CrossRefPubMed Bishop JA, Weinreb I, Swanson D, Westra WH, Qureshi HS, Sciubba J, et al. Microsecretory adenocarcinoma: a novel salivary gland tumor characterized by a recurrent MEF2C-SS18 Fusion. Am J Surg Pathol. 2019;43(8):1023–32.CrossRefPubMed
24.
Zurück zum Zitat Chiosea SI, Dacic S, Nikiforova MN, Seethala RR. Prospective testing of mucoepidermoid carcinoma for the MAML2 translocation: clinical implications. Laryngoscope. 2012;122(8):1690–4.CrossRefPubMed Chiosea SI, Dacic S, Nikiforova MN, Seethala RR. Prospective testing of mucoepidermoid carcinoma for the MAML2 translocation: clinical implications. Laryngoscope. 2012;122(8):1690–4.CrossRefPubMed
25.
Zurück zum Zitat Rooper LM, Argyris PP, Thompson LDR, Gagan J, Westra WH, Jordan RC, et al. Salivary mucinous adenocarcinoma is a histologically diverse single entity with recurrent AKT1 E17K mutations: clinicopathologic and molecular characterization with proposal for a unified classification. Am J Surg Pathol. 2021;45(10):1337–47.CrossRefPubMed Rooper LM, Argyris PP, Thompson LDR, Gagan J, Westra WH, Jordan RC, et al. Salivary mucinous adenocarcinoma is a histologically diverse single entity with recurrent AKT1 E17K mutations: clinicopathologic and molecular characterization with proposal for a unified classification. Am J Surg Pathol. 2021;45(10):1337–47.CrossRefPubMed
27.
Zurück zum Zitat Jo VY, Sholl LM, Krane JF. Distinctive patterns of ctnnb1 (beta-catenin) alterations in salivary gland basal cell adenoma and basal cell adenocarcinoma. Am J Surg Pathol. 2016;40(8):1143–50.CrossRefPubMed Jo VY, Sholl LM, Krane JF. Distinctive patterns of ctnnb1 (beta-catenin) alterations in salivary gland basal cell adenoma and basal cell adenocarcinoma. Am J Surg Pathol. 2016;40(8):1143–50.CrossRefPubMed
28.
Zurück zum Zitat Lee YH, Huang WC, Hsieh MS. CTNNB1 mutations in basal cell adenoma of the salivary gland. J Formos Med Assoc. 2018;117(10):894–901.CrossRefPubMed Lee YH, Huang WC, Hsieh MS. CTNNB1 mutations in basal cell adenoma of the salivary gland. J Formos Med Assoc. 2018;117(10):894–901.CrossRefPubMed
29.
Zurück zum Zitat Sato M, Yamamoto H, Hatanaka Y, Nishijima T, Jiromaru R, Yasumatsu R, et al. Wnt/beta-catenin signal alteration and its diagnostic utility in basal cell adenoma and histologically similar tumors of the salivary gland. Pathol Res Pract. 2018;214(4):586–92.CrossRefPubMed Sato M, Yamamoto H, Hatanaka Y, Nishijima T, Jiromaru R, Yasumatsu R, et al. Wnt/beta-catenin signal alteration and its diagnostic utility in basal cell adenoma and histologically similar tumors of the salivary gland. Pathol Res Pract. 2018;214(4):586–92.CrossRefPubMed
30.
Zurück zum Zitat Wilson TC, Ma D, Tilak A, Tesdahl B, Robinson RA. Next-generation sequencing in salivary gland basal cell adenocarcinoma and basal cell adenoma. Head Neck Pathol. 2016;10(4):494–500.CrossRefPubMedPubMedCentral Wilson TC, Ma D, Tilak A, Tesdahl B, Robinson RA. Next-generation sequencing in salivary gland basal cell adenocarcinoma and basal cell adenoma. Head Neck Pathol. 2016;10(4):494–500.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Chiosea SI, Miller M, Seethala RR. HRAS mutations in epithelial-myoepithelial carcinoma. Head Neck Pathol. 2014;8(2):146–50.CrossRefPubMed Chiosea SI, Miller M, Seethala RR. HRAS mutations in epithelial-myoepithelial carcinoma. Head Neck Pathol. 2014;8(2):146–50.CrossRefPubMed
32.
Zurück zum Zitat Cros J, Sbidian E, Hans S, Roussel H, Scotte F, Tartour E, et al. Expression and mutational status of treatment-relevant targets and key oncogenes in 123 malignant salivary gland tumours. Ann Oncol. 2013;24(10):2624–9.CrossRefPubMed Cros J, Sbidian E, Hans S, Roussel H, Scotte F, Tartour E, et al. Expression and mutational status of treatment-relevant targets and key oncogenes in 123 malignant salivary gland tumours. Ann Oncol. 2013;24(10):2624–9.CrossRefPubMed
33.
Zurück zum Zitat El Hallani S, Udager AM, Bell D, Fonseca I, Thompson LDR, Assaad A, et al. Epithelial-myoepithelial carcinoma: frequent morphologic and molecular evidence of preexisting pleomorphic adenoma, common HRAS mutations in PLAG1-intact and HMGA2-intact cases, and occasional TP53, FBXW7, and SMARCB1 alterations in high-grade cases. Am J Surg Pathol. 2018;42(1):18–27.CrossRefPubMedPubMedCentral El Hallani S, Udager AM, Bell D, Fonseca I, Thompson LDR, Assaad A, et al. Epithelial-myoepithelial carcinoma: frequent morphologic and molecular evidence of preexisting pleomorphic adenoma, common HRAS mutations in PLAG1-intact and HMGA2-intact cases, and occasional TP53, FBXW7, and SMARCB1 alterations in high-grade cases. Am J Surg Pathol. 2018;42(1):18–27.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Bishop JA, Gagan J, Baumhoer D, McLean-Holden AL, Oliai BR, Couce M, et al. Sclerosing polycystic “adenosis” of salivary glands: a neoplasm characterized by PI3K pathway alterations more correctly named sclerosing polycystic adenoma. Head Neck Pathol. 2020;14(3):630–6.CrossRefPubMed Bishop JA, Gagan J, Baumhoer D, McLean-Holden AL, Oliai BR, Couce M, et al. Sclerosing polycystic “adenosis” of salivary glands: a neoplasm characterized by PI3K pathway alterations more correctly named sclerosing polycystic adenoma. Head Neck Pathol. 2020;14(3):630–6.CrossRefPubMed
35.
Zurück zum Zitat Chiosea SI, Williams L, Griffith CC, Thompson LD, Weinreb I, Bauman JE, et al. Molecular characterization of apocrine salivary duct carcinoma. Am J Surg Pathol. 2015;39(6):744–52.CrossRefPubMed Chiosea SI, Williams L, Griffith CC, Thompson LD, Weinreb I, Bauman JE, et al. Molecular characterization of apocrine salivary duct carcinoma. Am J Surg Pathol. 2015;39(6):744–52.CrossRefPubMed
36.
Zurück zum Zitat Dalin MG, Desrichard A, Katabi N, Makarov V, Walsh LA, Lee KW, et al. Comprehensive molecular characterization of salivary duct carcinoma reveals actionable targets and similarity to apocrine breast cancer. Clin Cancer Res. 2016;22(18):4623–33.CrossRefPubMedPubMedCentral Dalin MG, Desrichard A, Katabi N, Makarov V, Walsh LA, Lee KW, et al. Comprehensive molecular characterization of salivary duct carcinoma reveals actionable targets and similarity to apocrine breast cancer. Clin Cancer Res. 2016;22(18):4623–33.CrossRefPubMedPubMedCentral
Metadaten
Titel
A Subset of Salivary Intercalated Duct Lesions Harbors Recurrent CTNNB1 and HRAS Mutations: A Molecular Link to Basal Cell Adenoma and Epithelial-Myoepithelial Carcinoma?
verfasst von
Anne C. McLean
Lisa M. Rooper
Jeffrey Gagan
Lester D. R. Thompson
Justin A. Bishop
Publikationsdatum
08.12.2022
Verlag
Springer US
Erschienen in
Head and Neck Pathology / Ausgabe 2/2023
Elektronische ISSN: 1936-0568
DOI
https://doi.org/10.1007/s12105-022-01513-x

Weitere Artikel der Ausgabe 2/2023

Head and Neck Pathology 2/2023 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …